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Introduction
Friedreich ataxia (FRDA [MIM 229300]), the most
prevalent inherited ataxia, is an autosomal recessive dis-
ease with onset in early childhood followed by an un-
remitting course that terminates with death in the fourth
or fifth decade of life. It occurs at a frequency of 1–2
per 50,000 individuals. FRDA is characterized clinically
by progressive gait and limb ataxia; signs of upper
motoneuron dysfunction including dysarthria, areflexia,
and loss of the senses of position and vibration; cardio-
myopathy; diabetes mellitus; and secondary skeletal ab-
normalities. The majority (195%) of patients with
FRDA are homozygous for large expansions of a GAA
triplet–repeat sequence (66–1800 triplets) locatedwithin
the first intron of the gene X25, which encodes the pro-
tein frataxin (Campuzano et al. 1996). The expansion
causes a severe reduction in the levels of frataxin, a
210–amino acid protein that is targeted tomitochondrial
matrix and that appears to play a crucial role in iron
homeostasis. The severity of the disease is directly cor-
related with the length of the expansion. A very small
minority of patients are compound heterozygotes for the
GAA expansion and for point mutations within theX25
gene. Chamberlain and coworkers have recently sum-
marized all point mutations described to date (Pook et
al. 2000).
In this review, we will discuss recent developments
that have increased our understanding of the effect of
the GAA expansion on transcription and replication.
Approaches used to investigate the unusual conforma-
tional properties of the GAA expansion and the unique
behavior of the expansion in cultured cells will be de-
scribed. Insights into the biogenesis of frataxin, includ-
ing processing of the precursor protein and import into
the mitochondria, will be summarized. We will describe
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advances made in the construction of mouse models for
the disease. Finally, we will discuss important advances
that have been made in deciphering the structure and
function of frataxin, and we will conclude with pros-
pects for therapy.
GAA Triplet–Repeat Expansion as an Impediment to
Transcription
RT-PCR and RNAse protection studies of RNA isolated
from lymphoblast cell lines of patients with FRDA who
were homozygous for the GAA expansion clearly dem-
onstrated that frataxin RNA levels were severely reduced
as a consequence of the expansion mutation. Several
groups have demonstrated that the GAA-repeat expan-
sion interferes with transcription. Bidichandani et al.
(1998) reported a length- and orientation-dependent in-
terference with in vitro transcription of GAA-repeat se-
quences, from patients with FRDA, consisting of 45, 79,
or 100 GAA repeats that were cloned downstream of a
bacteriophage T7 or a cytomegalovirus promoter. When
the template strand contained the GAA sequence, which
corresponds to the normal orientation of the GAA se-
quence within the X25 gene, the reduction was more
pronounced than when the reverse complement of the
expansion, or (TTC)n, was present on the template
strand.
Ohshima et al. (1998) examined the effect of the pres-
ence of GAA repeats—ranging in number from 9 to 270
and cloned from patients with FRDA into the vector
pSPL3—on splicing, gene expression, and replication.
RNAse protection products corresponding to the spliced
exon 1  2 transcript and to exon 1– and exon 2–con-
taining transcripts showed that increasing numbers of
GAA repeats lead to a reduction in the amount of ma-
ture transcript containing both exon 1 and 2 of the HIV
gp120 reporter gene containing GAA repeats . However,
the initiation of transcription and splicing were unaf-
fected, confirming that the repeats interfered with elon-
gation of transcripts rather than with their initiation or
splicing. Lower levels of GAA-repeat–containing plas-
mids were also recovered compared with the levels of
control plasmids, suggesting an inhibitory effect on rep-
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Figure 1 Proposed models for the formation of non–B DNA
conformations by GAA-repeat sequences. A, Intramolecular RRY tri-
plex, formed when the purine-rich strand dissociates from its com-
plementary strand and pairs by Hoogsteen bonding in an antiparallel
orientation with the major groove (only one DNA isoform is shown).
B, The triplex shown in A, paired with the GAA-containing transcript,
thereby further stabilizing the triplex (Bidichandani et al. 1998; Oh-
shima et al. 1998). C, A variation in the intramolecular triplex model,
in which the wave of negative supercoiling induced by RNA poly-
merase induces triplex formation, leading to a pause at the promoter
distal end of the structure (Grabczyk and Usdin 2000a). Binding of a
triplex-forming oligonucleotide (shown in red) to the nontemplate
strand can alleviate the transcriptional block by preventing formation
of the triplex (Grabczyk and Usdin 2000b). D, Association of two
triplexes to form “sticky DNA.” A strand-exchange model is depicted,
in which two circular plasmid molecules associate with each other at
the RRY triplex regions. The Y strands from the RRY triplexes reas-
sociate with the R looped region from the second triplex and recon-
figure to form hybrid RRY triplexes (Sakamoto et al. 1999).
lication. Again, the effects on transcription and repli-
cation were much more prominent when (GAA)n was
in the template strand.
Grabczyk and Usdin (2000a) studied the effect of
GAA tracts, in the absence of any other frataxin gene
sequences, on in vitro transcription by bacteriophage
T7 polymerase. A reduction in the amount of GAA-
containing transcripts was seen, an effect that was ex-
acerbated by both tract length and superhelicity. One
novel observation made by this group was that the tran-
scripts are truncated at the distal end of the GAA tract,
which accounts for the slightly different model for the
mode of action of the repeats (fig. 1C).
The length-dependent reduction in in vitro (Bidi-
chandani et al. 1998; Grabczyk and Usdin 2000a) and
in vivo (Ohshima et al. 1998) transcription of the tem-
plates used in the above studies is consistent with the
increase in severity—assessed as an earlier age at on-
set—of FRDA that occurs with an increased number of
GAA repeats. The orientation-dependent effect (Bidi-
chandani et al. 1998; Ohshima et al. 1998; Grabczyk
and Usdin 2000a) is consistent with the working model
for the mode of action of the expansion mutation (see
below).
Unusual DNA Structure Formed by GAA Expansion
The location of the GAA expansion in the first intron
of the frataxin gene raised immediate questions con-
cerning the resulting molecular underpinnings leading to
pathogenesis. Several mechanisms could be envisioned
for the reduction in transcript levels, including abnormal
splicing of the heteronuclear RNA, disruption of an en-
hancer element, or creation of a transcriptional block-
ade. No evidence for aberrantly spliced products was
apparent when RNAse protection studies were con-
ducted with probes that spanned exons 1 and 2, al-
though this method could not exclude short-lived tran-
scripts originating from the allele with the expansion
(Bidichandani et al. 1998). Enhancer activity was not
detected when a fragment containing the wild-type GAA
repeat and flanking sequence was cloned into an SV40
promoter-driven luciferase expression vector and as-
sayed for enhancer function in fibroblast cells (Bidi-
chandani et al. 1998). Tissue-specific enhancer activity
could not, of course, be ruled out by this assay. Bidi-
chandani et al. (1998) first demonstrated that the FRDA
expansion was likely to be associated with an unusual
DNA structure (Cavadini et al. 2000b). PCR-amplified
linear fragments including ∼1.5 kb of intron 1 sequence
in the context of the normal (9 GAA repeats) and ex-
panded (up to 350 repeats) alleles were probed with
osmium tetroxide, hydroxylamine, and diethylpyrocar-
bonate, chemicals typically used for the probing of un-
usual DNA structures such as DNA triplexes and cru-
ciform DNAs. These studies suggested the presence of a
non–B DNA structure that was hypothesized to most
likely represent an intramolecular triplex (fig. 1A). Re-
cently, in keeping with the finding that triplex DNA
structures are prone to increased mutagenesis, this group
has found evidence for enhanced mutagenesis (pointmu-
tations) in the sequence immediately flanking the ex-
panded GAA repeats (Bidichandani et al. 1999).
Wells, Pandolfo, and colleagues proposed a similar
intramolecular triplex model based on their investiga-
tions with GAA repeats in an in vivo transcription assay
(Bidichandani et al. 1998; fig. 1A, B). Further elegant
studies by this group have shed more light on the mo-
lecular nature of the transcriptional block posed by the
formation of a non–B DNA structure at the GAA-repeat
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expansion (Sakamoto et al. 1999). They noted that,
during standard agarose gel electrophoresis of linearized
(GAA)n-containing plasmid DNA, a portion of the DNA
migrated anomalously, with an apparent molecular
weight that was 2.4-fold greater than expected. Detailed
investigations indicated that the extent of retardation
was a function of location of the repeat within the linear
DNA and that negative supercoiling promoted its for-
mation. The slowly migrating DNA is P1-nuclease sen-
sitive and thermostable in the absence of EDTA, and its
formation is favored at neutral pH. The authors pos-
tulate that the GAA-rich sequences self-associate (see
fig. 1D) to form a novel DNA structure that they refer
to as “sticky DNA.” A (GAAGGA)65-repeat sequence
present in the first intron of the X25 gene of some in-
dividuals did not display the properties of sticky DNA,
suggesting an intrinsic preference for uninterrupted
(GAA)n sequences to form this structure (Ohshima et
al. 1999).
In a collaborative effort between the Pearson, Sinden,
and Gao laboratories, a detailed analysis of individual
GAA and TTC repeats was performed using the meth-
ods of nuclear magnetic resonance, UV melting, and gel
electrophoresis, as well as chemical and enzymatic prob-
ing (LeProust et al. 2000). This study highlighted the
structural diversity of these dynamically unstable re-
peats: Together, the GAA and TTC repeats were able
to form various structures, including parallel-stranded
duplexes, antiparallel (Watson-Crick) duplexes, and py-
rimidine-purine-pyrimidine (YRY) triplexes. Unlike the
CNG repeats, hairpin formation by either the GAA or
the TTC repeats was not readily detected. However, the
GAA repeat—but not the TTC repeat—was capable of
forming a metastable structure. Most interesting was
the observation of a very stable parallel duplex between
the complementary strands under physiological condi-
tions (the common Watson-Crick B-DNA duplexes are
antiparallel). Intriguingly, the parallel duplex could be
formed only between GAA strands and TTC strands
containing a 5′-hydroxyl (rather than a 5′-phosphate).
It may not be a coincidence that the 5′ ends of Okazaki
fragments, produced during semiconservative DNA rep-
lication, are transiently dephosphorylated to expose a
5′-hydroxyl group (Pohjanpelto and Holtta 1996). Per-
haps the transient state of the 5′ ends during DNA rep-
lication could facilitate the formation of alternative lo-
cal DNA structures, which may then serve as mutagenic
intermediates in the expansion process.
Studies using a single oligonucleotide composed of
both GAA and TTC repeats (Gacy et al. 1998; Mar-
iappan et al. 1999) demonstrated triplex formation in
the parallel orientation. However, triplex formation by
these designed oligonucleotides was forced by the jux-
taposition of the two repeats in a single DNA chain.
Formation of the purine-purine-pyrimidine (RRY) tri-
plex by this single oligonucleotide (Gacy et al. 1998;
Mariappan et al. 1999) contrasted with the YRY triplex
formed by either plasmid-borne (GAA)n7(TTC)n inserts
(Hanvey et al. 1988) or the mixture of individual GAA
and TTC strands (LeProust et al. 2000). On the basis
of their oligonucleotide studies, Gacy et al. (1998) pro-
posed an alternative model for intramolecular triplex
formation in the expansion process.
Germline and Somatic Variation in GAA Expansion
Length
The GAA expansion shows intergenerational variation
in length, with evidence for changes in the prezygotic
and postzygotic stages. Studies have shown that the ex-
panded alleles seen in patients arose from a small pool
of uninterrupted “large normal” alleles referred to as
“premutations.” Interruptions within the pure GAA
triplet repeats impeded these large normal alleles from
expanding into disease-causing alleles. De Michele et al.
(1998) have noted that premutation alleles can undergo
large expansions in a single generation. Expanded GAA
repeats can expand or contract when transmitted
through the female germline. In contrast, contractions
are favored in male transmission. This is attributed to
postzygotic mechanisms, because shorter expansions are
seen in sperm DNA when compared with lymphocyte
DNA (prezygotic mechanism). However, evidence for
postzygotic variation in repeat number has also been
suggested, because the degree of repeat contraction in
the sperm is greater than that actually seen in intergen-
erational transmission and because the overall length of
expanded alleles is shorter in homozygous versus het-
erozygous carriers.
We have noted reversion of the expanded GAA triplet
repeat to a normal size in a patient with an atypically
mild phenotype. This contraction was seen in two in-
dependent peripheral blood samples (Bidichandani et
al. 1999). It is unclear whether somatic mosaicism for
the fully contracted allele is responsible for the milder
phenotype.
In contrast with other triplet-repeat expansions, sig-
nificant somatic variation has been seen for the GAA
expansion (Bidichandani et al. 1999). Pronounced
length variation was detected in serially passaged lym-
phoblastoid cells from individuals who were homozy-
gous or heterozygous for the expansion (Bidichandani
et al. 1999). Contractions and expansions were ob-
served with equal frequency and magnitude. Hellen-
broich et al. (2001) used small-pool PCR to examine
the expansion length in leukocytes and foundmosaicism
for the length of the repeat, with differences in length
that were up to 1,000 triplets per genome. A significant
correlation was found between the size of the largest
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allele and the range of mosaicism (Hellenbroich et al.
2001).
Biogenesis of Frataxin
The FRDA gene encodes a precursor form of frataxin
(Babcock et al. 1997; Wilson and Roof 1997). Positively
charged presequences with the general features of mi-
tochondrial matrix–targeting signals are present at the
N-termini of all known frataxin precursors from yeast,
mammals, and other eukaryotes (Gibson et al. 1996;
Canizares et al. 2000). Human frataxin (GenBank ac-
cession number Q16595) has been detected at thematrix
side of the inner mitochondrial membrane, by immu-
noelectron microscopy (Campuzano et al. 1997), and
yeast frataxin (Yfh1p [GenBank accession number
Q07540]) has been found to behave like a solublematrix
protein upon fractionation of mitochondria (Branda et
al. 1999a; Geissler et al. 2000). Koenig and colleagues
first noted that, whereas the precursors of most mito-
chondrial matrix proteins are subjected to a single pro-
teolytic event upon import, frataxin is processed to its
mature form in two steps, at least one of which was
catalyzed by the general mitochondrial-processing pep-
tidase (MPP) (Koutnikova et al. 1998). The implication
that some unique requirements might underlie mito-
chondrial import and the processing of frataxin drew
immediate attention, especially in light of the fact that
a reduction in the levels of—and not a loss of function
of—frataxin is the most frequent cause of FRDA (Cam-
puzano et al. 1996, 1997). Important strides in the def-
inition of the main steps and molecular components in-
volved in the biogenesis of frataxin have since been
made, primarily through studies of the yeast and human
proteins.
Mitochondrial Import and Processing of Frataxin
The mitochondrial targeting signals of yeast and human
frataxin consist of 51 and 55 amino acids, respectively
(Adamec et al. 2000; Cavadini et al. 2000a; Gordon et
al. 2001). During or immediately after translocation, the
targeting signal of Yfh1p is cleaved twice by MPP, be-
tween residues 20 and 21 and residues 51 and 52, gen-
erating an intermediate and a mature form (Knight et
al. 1998; Branda et al. 1999a; Adamec et al. 2000; Gor-
don et al. 2001). This pattern of processing is unusual,
given that most precursors are cleaved only once byMPP
to generate the mature form (Neupert 1997). In addition
to MPP, two components of the mitochondrial protein
import machinery, Tim44 and Ssq1, are also required
for efficient production of the intermediate (Geissler et
al. 2000) and mature form (Knight et al. 1998; Voisine
et al. 2000) of Yfh1p, possibly by influencing protein
folding and making the two cleavage sites more acces-
sible to MPP.
Additional requirements appear to influence the mat-
uration of mammalian frataxin. Koenig and colleagues
first observed cleavage of the mouse frataxin precursor
to a product with an apparent MW of 21 kDa, larger
than the form of frataxin detected in normal mouse or
human tissues (∼18 kDa) (Koutnikova et al. 1998),
which is also the form that is reduced in FRDA patients
(Campuzano et al. 1997). It was later shown that both
a ∼21 kDa and a ∼18 kDa form are produced by se-
quential cleavage of the human frataxin precursor by
MPP, and the two cleavage sites were mapped between
residues 41–42 and 55–56 (Branda et al. 1999a; Ca-
vadini et al. 2000a). The second cleavage was shown
to be very slow, however, limiting the overall rate at
which the mature form was produced by purified MPP
or within mitochondria (Cavadini et al. 2000a). These
kinetics may explain why the second cleavage was not
detected in another study of human frataxin biogenesis
(Gordon et al. 1999). Given that either rat or yeastMPP
was used in all of these studies, the observed kinetics
may also reflect a lack of species specificity between the
peptidase and its substrate.
These observations collectively have raised the inter-
esting possibility that the steady-state levels of mam-
malian frataxin may be regulated through specific in-
teractions with MPP. In this respect, the fact that mouse
frataxin was found to interact with the b and not the
a subunit of MPP (Koutnikova et al. 1998) is intriguing,
given our current knowledge that a-MPP is responsible
for substrate binding, whereas b-MPP is primarily in-
volved in catalysis (reviewed by Adamec et al. [2001]).
Variable Effects of FRDA Point Mutations on the
Biogenesis of Human Frataxin
Interaction between the mouse frataxin precursor and
b-MPP is inhibited by two of the most common FRDA
point mutations, I154F and G130V (Koutnikova et al.
1998). The I154F mutation was further found to affect
the processing of human frataxin in COS cells (Kout-
nikova et al. 1998) but not in vitro (Gordon et al. 1999).
In more recent studies, the W173G mutation inhibited
the second processing step both in vitro and in yeast,
whereas the G130V mutation had no obvious effect on
frataxin processing (Cavadini et al. 2000a, 2000b).
Although MPP often cleaves at position 2 or 3
from an arginine residue (Gavel and von Heijne 1990),
both the overall secondary structure of the presequence
as well as structural elements in the mature portion of
the precursor molecule are important determinants for
substrate recognition by this peptidase (reviewed by
Adamec et al. [2001]). Thus, it is not surprising that
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FRDA point mutations far from the actual MPP cleav-
age sites—especially mutations such as I154F or
W173G, which are predicted to cause major changes in
the protein fold (Dhe-Paganon et al. 2000)—can affect
recognition and/or processing of frataxin by MPP. One
caveat is that heterologous experimental systems may
not precisely reproduce the consequences of FRDA
point mutations in human mitochondria. This possi-
bility is especially suggested by the diversity of effects
associated with the I154F or G130V mutation in COS
cells, yeast, or in vitro assays (Koutnikova et al. 1998;
Gordon et al. 1999; Cavadini et al. 2000a, 2000b).
Thus, studies of protein import in human cells or in
isolated mitochondria, as well as processing experi-
ments using purified human MPP, will be required to
establish with certainty the functional effects of these
and other point mutations.
Possible Role of the Mitochondrial Import Machinery
in FRDA
The studies summarized above have revealed unique
requirements for the efficient import and processing of
frataxin. Although some caution may be necessary when
extrapolating from model systems to humans, this in-
formation suggests that certain components of the mi-
tochondrial protein-import machinery may influence the
pathogenesis and clinical variability of FRDA. For in-
stance, there may exist genetic variants of MPP associ-
ated with reduced rates of frataxin processing, which
would presumably lower the threshold for phenotypic
expression of expanded FRDA alleles. In addition, given
that both translocation and processing of the frataxin
precursor are ATP-dependent (Geissler et al. 2000; Vois-
ine et al. 2000), respiratory chain defects such as those
associated with FRDA (Rotig et al. 1997; Lodi et al.
1999; Bradley et al. 2000) might easily trigger a vicious
cycle in which frataxin deficiency would initially cause
a decrease in ATP production, and this would, in turn,
impair protein import and exacerbate frataxin defi-
ciency. The genetic and biochemical information nec-
essary to begin to address these possibilities in patients
is now available. The identification of genetic modifiers
and synergistic pathogenic mechanisms and the defining
of strategies for the treatment of FRDA will be signifi-
cant goals of these studies.
Role of Frataxin in Iron Homeostasis
The first insights into the function of frataxin came from
studies in yeast, which showed that a lack of Yfh1p
impairs iron export from the mitochondrion (Radisky
et al. 1999), which leads to cytoplasmic iron depletion,
induction of plasma membrane proteins involved in iron
uptake, and mitochondrial iron overload (Babcock et al.
1997; Foury and Cazzalini 1997; Radisky et al. 1999).
Iron-induced oxidative damage was postulated to be the
most probable cause underlying the loss of mtDNA and
iron-sulfur proteins characteristic of Yfh1p-deficient
yeast (yfh1D) (Babcock et al. 1997; Foury and Cazzalini
1997).
A direct involvement of Yfh1p in the biosynthesis of
iron-sulfur clusters has been proposed more recently
(Foury 1999; Lutz et al. 2001). This view has been
challenged by another study showing that a lack of
Yfh1p does not result in any significant loss of iron-
sulfur–containing enzyme activities if mitochondrial
iron accumulation and, hence, oxidative damage to
iron-sulfur proteins can be prevented (Chen and Kaplan
2000). Differences in the approaches used to assess the
functionality of iron-sulfur enzymes may explain these
contrasting results. In any case, it is clear that the
maintenance of functional mitochondrial iron-sulfur en-
zymes, whether directly or indirectly, is a critical aspect
of the role played by Yfh1p in global cellular iron
homeostasis (Foury and Talibi 2000) and in mitochon-
drial respiratory function (Babcock et al. 1997; Foury
and Cazzalini 1997; Koutnikova et al. 1997; Wilson
and Roof 1997; Branda et al. 1999b).
Iron-Induced Oxidative Damage and the Pathogenesis
of FRDA
A large body of studies has addressed the important
questions of whether frataxin plays a role in iron homeo-
stasis in humans and what the implications are for the
pathogenesis of FRDA. Chimeric Yfh1p-human frataxin
and full-length human frataxin constructs allow partial
and full complementation of yfh1pmutants, respectively,
including the ability to maintain normal mitochondrial
iron levels and aconitase activity (Wilson and Roof
1997; Cavadini et al. 2000b). Conversely, expression in
yfh1D yeast of a full-length frataxin construct containing
the W173G mutation resulted in increased mitochon-
drial iron levels and loss of respiratory function (Ca-
vadini et al. 2000b) consistent with the severe clinical
presentation associated with theW173Gmutation (Cos-
see et al. 1999). These basic studies have therefore dem-
onstrated that human frataxin participates in iron ho-
meostasis, at least in the context of yeast mitochondria.
Beginning with an early report of iron deposits in
hearts of patients with FRDA (Lamarche et al. 1980),
pathological and clinical studies have shown that the
consequences of frataxin defects are indeed similar be-
tween the yeast model and mammalian cells. Granular
iron deposits suggestive of mitochondrial iron overload,
as well as signs of oxidative damage including multiple
iron-sulfur enzyme defects and loss of mtDNA, have
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been observed in hearts from these patients (Rotig et
al. 1997; Bradley et al. 2000), and increased levels of
mitochondrial iron and hypersensitivity to oxidative
stress have been detected in the patients’ cultured cells
(Delatycki et al. 1999; Wong et al. 1999). Elevated se-
rum levels of the transferrin receptor, indicative of lim-
ited cytoplasmic iron supplies (Wilson et al. 2000) and
of malondialdehyde, a marker of lipid peroxidation
(Emond et al. 2000), have also been noted in patients.
The pathogenic importance of oxidative damage in
FRDA is further underscored by two studies in which
administration of the antioxidant idebenone led to a
reduction in myocardial hypertrophy in 3 patients (Rus-
tin et al. 1999) and to a decrease in urine levels of
8-hydroxy-2′-deoxyguanosine, a marker of oxidative
DNA damage, in 33 patients (Schulz et al. 2000). In
addition, conditional frataxin knockout mice exhibit
multiple iron-sulfur enzyme deficiencies and mitochon-
drial iron accumulation (Puccio et al. 2001) (see below).
Together, these findings indicate that frataxin controls
a critical iron pool within mitochondria. This function
is clearly important for maintenance of overall cellular
iron homeostasis and for protection from iron-induced
oxidative damage.
Mice with Complete or Tissue-Specific Deficiency
of Frataxin
The first attempt to create a mouse model for FRDA
involved the creation of a homozygous deletion of exon
4 of Frda (Cossee et al. 2000). The deletion is predicted
to create a truncated protein that lacks more than half
of the frataxin protein sequence, including the most con-
served domain of the protein (Cossee et al. 2000). This
mutation is embryonically lethal a few days after im-
plantation, suggesting that frataxin is essential during
development. Both apoptotic and necrotic features were
noted in the Frda null embryos. Notably, there is no
evidence for accumulation of iron. FRDA patients ap-
pear to tolerate frataxin deficiency during development.
One possible explanation is that humans are aided by
compensatory mechanisms for the handling of frataxin
deficiency. The other, more likely, possibility stems from
the observation that the vast majority of patients with
FRDA are homozygous for GAA expansions. As noted
above, the expansion appears to pose a transcriptional
block, and it is quite possible that just enough frataxin
is produced in patients with FRDA to allow normal de-
velopment, with the deficiency posing problems gradu-
ally (Cossee et al. 2000). Indeed, low levels of frataxin
are expressed in lymphoblast lines from patients with
FRDA who have expansions, and this expression is di-
rectly correlated with the size of the expansion (Cam-
puzano et al. 1997).
Koenig and coworkers recently generated two con-
ditional mouse models for FRDA through creation of
an exon 4 deletion in striated muscle tissue or in neural
and cardiac muscle tissue, through use of a Cre trans-
gene under the control of tissue-specific promoters (Puc-
cio et al. 2001). Frataxin is absent in skeletal and cardiac
tissue of the conditional line referred to as the “MCK
mutant,” in which the Cre transgene, which removes
exon 4 by driving recombination at lox p sites sur-
rounding the exon, is under the control of the muscle
creatine kinase promoter. These mice start to loseweight
at age ∼7 wks and have a life expectancy of 76 10
d, with a 29% weight reduction at death. The NSE
mutant, in which the Cre transgene is driven by the
neuron-specific enolase promoter, has a shorter life ex-
pectancy of days, with a 41% weight reduction24 9
at death. The NSE mutants have a progressive neuro-
logical phenotype with ataxia, hunched stance, and loss
of the sense of position. Frataxin is absent in skeletal
and cardiac tissue. Cardiac hypertrophy, the predomi-
nant cause of death in patients with FRDA, is seen in
both mutants. Time-dependent iron accumulation was
noted in the hearts of MCK mutants but, importantly,
the iron deposits followed—and, therefore, were ap-
parently not responsible for—the cardiac pathology.
Multiple Fe-S enzyme deficiencies similar to those in
patients were noted and were seen to occur in parallel
with the pathology in the CNS and heart of the mutant
lines. These lines recapitulate the major biochemical and
pathophysiological features of the human disease and
will be very useful not only for an understanding of the
relationship between Fe-S enzyme deficiency and the
accumulation of iron but also for the provision of useful
models for the testing of therapeutic strategies based on
antioxidants and/or iron chelators.
Mechanistic and Structural Studies of Frataxin
A continuous supply of iron is needed in mitochondria,
primarily for the biosynthesis of heme and iron-sulfur
clusters, both of which require ferrous iron in vitro and,
most likely, in living cells as well (reviewed by Ferreira
et al. [1995] and Muhlenhoff and Lill [2000]). Iron
transport across the inner mitochondrial membrane is
an energy-dependent process with an absolute require-
ment for reducing equivalents provided by the respira-
tory chain (reviewed by Gattermann et al. [1993]), in-
dicating that iron must cross the inner membrane in the
ferrous form. Under aerobic conditions at physiologic
pH, however, Fe2 is rapidly oxidized by dioxygen to
Fe3, a reaction that leads to a substantial decrease in
iron solubility (from 108 M to 1018 M) (Williams
1982) and that generates superoxide radical (Halliwell
1978). In addition, Fe2 can interact with hydrogen per-
oxide, a by-product of respiration, to give hydroxyl rad-
ical, which is the most reactive oxygen species known
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Figure 2 A, Proposed function of frataxin in normal mitochon-
dria. B, Consequences of frataxin deficiency. Ferrochelatase catalyzes
the final step of the heme biosynthetic pathway, which involves the
insertion of Fe2 into protoporphyrin IX (IX). This enzyme is localized
to the matrix side of the inner mitochondrial membrane and is believed
to be able to bind Fe2 immediately after its reduction by the respi-
ratory chain (Taketani et al. 1986). The initial step in the iron-sulfur
(Fe/S) cluster biosynthetic pathway involves Fe2 binding by the Isu1
and Isu2 proteins, which serve as scaffolds for cluster assembly (Muhl-
enhoff and Lill 2000). These proteins are localized to themitochondrial
matrix and may depend on frataxin for a sufficient supply of Fe2.
Both decreased biosynthesis and oxidative damage may contribute to
Fe/S enzyme defects. DW p mitochondrial inner-membrane potential.
(Gutteridge et al. 1981). Thus, it is essential for the
mitochondrion to maintain a supply of Fe2 but at the
same time prevent its participation in radical reactions.
Work by Isaya and colleagues has revealed that the
involvement of Yfh1p in iron export may reflect a more
general role of this protein as an iron ligand in the
mitochondrial matrix. To elucidate the mechanism of
action of frataxin, they have expressed the mature form
of Yfh1p in Escherichia coli and analyzed the ability of
the isolated protein to bind iron in vitro (Adamec et al.
2000). Titration of isolated Yfh1p with increasing con-
centrations of a ferrous iron salt under aerobic condi-
tions induced stepwise assembly of a regular spherical
multimer with a molecular weight of 1106 and the abil-
ity to sequester 13,000 atoms of iron. A high–molecular-
weight (1600,000) form of Yfh1p was also detected in
yeast mitochondria, and when yeast cells were grown
in the presence of 55Fe, immunoprecipitates of this form
were found to contain 116 atoms of 55Fe per molecule
of Yfh1p (Adamec et al. 2000). On the basis of these
findings, these investigators have proposed that the
function of Yfh1p is to bind iron and to keep it in a
soluble and bioavailable form. Interestingly, Flatmark
and Romslo (1975) reported 125 years ago that a pool
of “non-heme non–iron-sulfur” iron could be recovered
from the matrix of isolated rat liver mitochondria in a
large hydrophilic complex with molecular weight 1106.
They suggested that a macromolecule distinct from fer-
ritin might be responsible for the binding of iron in a
soluble and stable form in the mitochondrial matrix.
Indeed, a more recent study has revealed that isolated
Yfh1p binds Fe2 and keeps it in reduced and readily
available form in aqueous solution at physiologic pH
(J. Adamec, E.E. Arias, A. Mangravita, G.C. Ferreira,
G. Isaya, unpublished data). The duration of this effect
ranges from several minutes to 11 h, depending on the
experimental conditions. During this time, Yfh1p can
protect other biomolecules from iron-induced oxidative
damage and can provide Fe2 ions for heme synthesis
in the presence of ferrochelatase and protoporphyrin
IX. The iron that remains bound to Yfh1p is otherwise
progressively oxidized and stored in a soluble form
within the assembled protein.
These findings suggest that the function of frataxin
is to bind Fe2 and to decrease the rate of Fe2 oxidation
to Fe3 (fig. 2A). In this manner, frataxin could promote
iron export to the cytoplasm or its utilization by the
iron-sulfur cluster or heme biosynthetic pathways, pre-
venting iron participation in radical reactions. Such
properties could explain the activation of oxidative
phosphorylation associated with frataxin overexpres-
sion in cultured cells (Ristow et al. 2000), assuming that
respiration is normally limited by the levels of redox-
active Fe2 and/or the rates of iron-sulfur cluster or
heme biosyntheses. Moreover, through its modulation
of iron oxidation, frataxin could provide a means of
storing ferric iron in soluble and possibly useful form,
similar to the iron stored in ferritin (reviewed by Har-
rison and Arosio [1996]). Conversely, in the case of
frataxin deficiency, iron would no longer be efficiently
exported or utilized, causing immediate oxidative dam-
age and progressive iron accumulation (fig. 2B). This
sequence of events is consistent with the phenotype of
conditional frataxin-deficient mice, in which loss of
iron-sulfur enzyme activities is an early effect, whereas
mitochondrial iron deposition is time-dependent (Puc-
cio et al. 2001). The proposed model may also explain
the early embryonic lethality, without iron accumula-
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tion, induced by deletion of the mouse frataxin gene
(Cossee et al. 2000). It is possible that in the absence
of frataxin a significant fraction of the iron entering the
mitochondrion may be neither used nor detoxified. This
condition may result in embryonic cell death before
detectable levels of iron can accumulate. Interestingly,
early embryonic lethality is also associated with inac-
tivation of the mouse H-ferritin gene (Ferreira et al.
2000), suggesting that both ferritin and frataxin are
critically required for iron bioavailability and iron stor-
age during development.
The three-dimensional structures of human and bac-
terial frataxin have revealed a novel fold characterized
by a highly conserved negatively charged surface (Cho
et al. 2000; Dhe-Paganon et al. 2000; Musco et al.
2000). The negatively charged surface is similar to the
anionic surface involved in the iron-storage mechanism
of ferritin (Dhe-Paganon et al. 2000), and human fra-
taxin may utilize a second, uncharged surface to assem-
ble with itself and form a negatively charged iron-stor-
age cavity similar to that of Listeria innocua ferritin
(Musco et al. 2000). Indeed, high–molecular-weight
forms of frataxin can be detected by gel filtration or
other nondenaturing approaches in human and mouse
tissues as well as in yeast cells expressing the human
protein (Airoldi et al. 2000; P. Cavadini and G. Isaya,
unpublished data). On the other hand, in testing a re-
combinant form of human frataxin, Pastore and col-
leagues did not detect any iron-binding or self-assembly
activity (Musco et al. 2000). This suggests that, whereas
Yfh1p is capable of undergoing self-assembly in vitro,
human frataxin may require molecular chaperones or
other factors that remain to be investigated.
Conclusions and Prospects for Therapy
Since the discovery of the FRDA gene (Campuzano et
al. 1996) and the seminal observation that frataxin me-
diates cellular iron homeostasis in yeast (Babcock et al.
1997), the function of frataxin has been studied by ge-
netic and biochemical means in a variety of systems,
providing insights into the importance of mitochondrial
iron metabolism and into the risks associated with de-
fects in this process. Evidence of increased oxidative
stress in patients with FRDA and of the promising effects
of idebenone (Rustin et al. 1999; Schulz et al. 2000) has
provided a strong rationale for the development of treat-
ments that may inactivate reactive radicals or mobilize
iron from mitochondria, thereby correcting the conse-
quences of frataxin deficiency. Inhibition of the forma-
tion of the abnormal DNA structure formed by the GAA
expansions represents an alternative strategy that could
potentially ameliorate frataxin deficiency. Grabzyck and
Usdin (2000b) have recently shown that oligodeoxyri-
bonucleotides designed to block particular types of tri-
plex formation lead to specific and concentration-de-
pendent increases in full-length transcript upon in vitro
transcription with bacteriophage T7 RNA polymerase.
These studies, which were conducted with artificial GAA
tracts, are a promising avenue for further exploration.
Additional studies of GAA expansions, within the mo-
lecular and cellular context of the X25 gene as seen in
FRDA patients, will be essential in order to engender
further support for this novel avenue of treatment.
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